Sitbon, Alexandre
Hauw-Berlemont, Caroline
Mebarki, Miryam
Heming, Nicholas
Mayaux, Julien
Diehl, Jean-Luc
Demoule, Alexandre
Annane, Djillali
Marois, Clémence
Demeret, Sophie
Weiss, Emmanuel
Voiriot, Guillaume
Fartoukh, Muriel
Constantin, Jean‐Michel
Mégarbane, Bruno
Plantefève, Gaëtan
Boucher-Pillet, Hélène
Churlaud, Guillaume
Cras, Audrey
Maheux, Camille
Pezzana, Chloé
Diallo, Mamadou Hassimiou
Lebbah, Said
Ropers, Jacques
Salem, Joe-Elie
Straus, Christian
Menasché, Philippe
Larghero, Jérôme
Monsel, Antoine http://orcid.org/0000-0002-9647-7043
Benchetrit, Déborah
Bonvallot, Harold
Charbonnier-Beaupel, Fanny
Dhib-Charfi, Meriem
Delmotte, Pierre Romain
Kone, Assitan
Le Corre, Marine
Metz, Carole
Puybasset, Louis
Vezinet, Corinne
,
Funding for this research was provided by:
Direction Générale de l’offre de Soins (PHRC COVID-19 2020)
Agence Nationale de la Recherche (ANR Flash COVID-19)
Article History
Received: 29 December 2023
Accepted: 10 April 2024
First Online: 19 April 2024
Declarations
:
: The National Review Board of Île-de-France III approved the trial (CNRIPH 20.03.26.39722) “<i>Cell therapy with umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-associated acute respiratory distress syndrome (ARDS)—STROMA-COV-2 study</i>” on March, 27, 2020. The clinical trial was authorized by the French National Agency for Medicines and Health Products Safety (EudraCT 2020-001287-28). Written informed consent was obtained from patients or a legally designated representative. This clinical study was conducted in full compliance with the Declaration of Helsinki.
: Not applicable.
: AD declared grants or contracts from Philips, Fisher & Paykel; French Ministry of Health; Respinor; Lungspacer; consulting fees from Lungspacer, Respinor; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Fisher & Paykel, Getinge, Lungspacer, Gilead, Lowenstein, Astra; support for attending meetings and/or travel from Fisher & Paykel, Lungspacer; received equipment, materials, drugs, medical writing, gifts or other services from Lungspacer, Respinor. MF declared grants or contracts from BioMérieux and MSD; French Ministry of Health; consulting fees from Pfizer; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Fisher & Paykel and Biomérieux; participation on a data safety monitoring board or advisory board. No conflict of interests is reported for other authors.